TCM
NEO icon

Teza Capital Management’s NeoGenomics NEO Stock Holding History

Teza Capital Management’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,341
Closed -$180K – 672
2023
Q1 		$180K Buy
+10,341
New +$147K 0.04% 473

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Teza Capital Management's NEO Position: Q2 2023 in Review

Teza Capital Management sold out of NeoGenomics (NEO) in Q2 2023, closing a stake of 10,341 shares — an estimated $180K sold.

Teza Capital Management first reported a position in NEO in Q1 2023 and held it in 1 quarter. The position peaked at $180K in Q1 2023. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2023.

  • Teza Capital Management reported no remaining NeoGenomics position as of Q2 2023 after selling out during the quarter.
  • Teza Capital Management sold 10,341 NeoGenomics shares in Q2 2023, an estimated $180K.
  • Teza Capital Management first reported a position in NeoGenomics in Q1 2023 and held it in 1 quarter.
  • Teza Capital Management's NeoGenomics position peaked at $180K in Q1 2023.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2023.

Based on Teza Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.